Abstracts

2017 ASCO - Chicago, IL

SEER study of breast cancer-specific mortality in patients with lobular tumors treated based on Recurrence Score results.
Baehner FL, Shak S, Miller DP, Petkov VI.
Abstract 11568

Prospective WSG phase III PlanB trial: Final analysis of adjuvant 4×EC→4×doc vs. 6×docetaxel/cyclophosphamide in patients with high clinical risk and intermediate-to-high genomic risk HER2-negative early breast cancer.
Harbeck N, Gluz O, Clemens MR, Malter W, Reimer T, Nuding B, Aktas B, Stefek A, Pollmanns A, Lorenz-Salehi F, Uleer C, Krabisch P, Kummel S, Liedtke C, Shak S, Wuerstlein R, Christgen M, Kates R, Kreipe HH, Nitz U.
Abstract 504

Performance of the 21-gene assay standard cutpoints of 18 and 31 in HR+, HER2-negative invasive breast cancer while waiting for TAILORx mid-range Recurrence Score results.
Miller DP, Petkov VI, Shak S.
Abstract 537

Refined estimates of local recurrence risks and the impact of the DCIS Score adjusting for clinico-pathological features: meta-analysis of E5194 and Ontario DCIS cohort studies.
Rakovitch E, Gray RJ, Baehner FL, Miller DP, Sutradhar R, Crager M, Gu S, Nofech-Mozes S, Badve SS, Hanna W, Hughes LL, Wood WC, Paszat LF, Shak S, Sparano JA, Solin LJ.
Abstract 528

Clinical outcomes in ER+ HER2-negative breast cancer where treatment decisions incorporated the 21-gene Recurrence Score: elderly (≥70 yrs) vs younger patients.
Stemmer SM, Steiner M, Rizel S, Baruch NB, Soussan-Gutman L, Bareket-Samish A, Nisenbaum B, Isaacs K, Fried G, Rosengarten O, Peretz T, Svedman C, McCullough D, Klang S, Zidan J, Ryvo L, Kaufman B, Shak S, Liebermann N, Geffen DB.
Abstract 543

Treatments/clinical outcomes in ER+ HER2-negative breast cancer where treatment decisions were Recurrence Score-guided: analysis by histologic subtype.
Stemmer SM, Steiner M, Rizel S, Baruch BN, Geffen DB, Soussan-Gutman L, Bareket-Samish A, Nisenbaum B, Isaacs K, Fried G, Rosengarten O, Uziely B, Svedman C, McCullough D, Klang S, Evron E, Karminsky N, Goldberg H, Steven S, Liebermann N.
Abstract e12053

A 17-gene panel for prediction of adverse surgical pathology in the setting of MRI-guided prostate biopsy.
Salmasi A, Said JW, Raman S, Shindel AW, McCullough D, Bailey H, Rothney M, Marks LS, Febbo PG, Reiter RE.
Abstract 5063

Association of risk of clinical recurrence and prostate cancer death with a 17-gene genomic prostate score (GPS) value <20.
Febbo PG, Crager M, Burke E, Lawrence HJ, Cullen J, Klein EA.
Abstract 5074

Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: Validation of the 16-gene Recurrence Score in stage III patients.
Escudier BJ, Rini BI, Martini JF, Chang WY, Breza J, Magheli A, Svedman C, Lopatin M, Knezevic D, Goddard AD, English PA, Li R, Lin X, Valota O, Cartenì G, Staehler MD, Motzer RJ, Ravaud A.
Abstract 4508

2017 AUA - Boston, MA

A diagnostic biopsy-based Genomic Prostate Score as an independent predictor of prostate cancer death and metastasis in men with localized prostate cancer
Van Den Eeden S, Zhang N, Shan J, Quesenberry C, Han J, Tsiatis A, Lu R, Lawrence J, Febbo P, Presti J

A 17-Gene Panel for Prediction of Adverse Pathology at Radical Prostatectomy: Prospective Validation
Eggener S, Richardson T, Rosenberg S, Goldfischer E, Lu R, Shindel A, Bennett J, Karsh L, Korman H, Febbo P, Denes B

Impact of the 17-gene Panel On Active Surveillance Persistence in Contemporary Urologic Practices: an Interim Analysis in an Observational Cohort
Eure G, Germany R, Given R, Glowacki R, Richardson T, Goldfischer E, Lu R, Shindel A, Bennett J, Febbo P, Denes B

A multi-center analysis of prostate cancer (PCa) treatment among Veterans following introduction of the 17-gene Genomic Prostate Score (GPS) assay
Lynch J, Rothney M, Salup R, Ercole C, Mathur S, Duchene D, Basler J, Hernandez J, Liss M, Porter M, Wright JL, Risk M, Garzotto M, Efimova O, Kemeter M, Denes B, Febbo P, Dash A

2017 ASBrS - Las Vegas, NV

The 12-gene Oncotype DX Breast DCIS Score assay: A summary of clinical evidence and commercial experience.
Alvarado M, McCullough D, Lau A, Baehner FL, Stöppler MC.
Poster #257283.
(To access the abstract, please refer to page 176 on The American Society of Breast Surgeons 2017 Official Proceedings)

2017 St. Gallen International Breast Cancer Conference - Vienna, Austria

PONDx, prospective multicenter study of the Oncotype DX breast cancer assay: Real life utilization in French clinical practice.
Curtit E, Vannetzel JM, Catala S, Darmon JC, Spaeth D, Mansi L, Varette C, Furtos-Fanget C, Mouysset JL, Pivot X.
Poster #P114

PONDx: A prospective multicenter French study of the 21-gene assay: Impact on treatment selection in patients with high-risk breast cancer.
Gligorov J, Bourgeois H, Dohollou N, Dewas S, Wassermann J, Tixier L, Bourgeois D, Genet D, Coscas Y, Khayat D.
Poster #P115

Use of the 21-gene Oncotype DX Breast Recurrence Score assay in the neoadjuvant treatment setting.
Robidoux A, McCullough D, Lau A, Stöppler M, Chao C.
Poster #P171

A pooled analysis of studies evaluating the impact of multi‐gene assay testing on adjuvant treatment decisions for women with node‐positive breast cancer.
Braybrooke J, Eiermann W. Poster
#P203

Change in treatment decisions according to Oncotype DX Recurrence Score in node positive and negative, estrogen-receptor positive, HER2 negative breast cancer in a single institution.
Gasol-Cudós A, Morales Murillo S, Panadés Siurana MJ, Vilardell Villellas F, Canosa Morales C, Mele Olive J, Iglesias Martinez E, Salud Salvia A.
Poster #P211

Institutional experience with Oncotype DX DCIS assay in radiation treatment plan of DCIS of the breast.
Calin A, De Ingunza L, Cebollero M, Lozano MA.
Poster #P212

Five‐year results of the prospective Phase III WSG PlanB trial confirm prognostic impact of 21‐gene Recurrence Score in high‐risk HR+/HER2‐ early breast cancer patients with 1‐3 involved lymph nodes.
Gluz O, Nitz U, Christgen M, Kates R, Clemens M, Nuding B, Shak S, Würstlein R, Kreipe H, Harbeck N.
Poster #P213

Oncotype DX Breast Recurrence Score (RS) distribution in primary breast cancer patients in Germany.
Hartkopf A, Wallwiener M, Andress J, Walter C, Chao C, Turner M, Weidenauer H, Hahn M, Taran A.
Poster #P216

Defining clinical utility for the 21-gene Oncotype DX Breast Recurrence Score assay in hormone receptor-positive, HER2-negative breast cancer.
Lau A, Miller DP, Davison D, Rothney M, Borgen P.
Poster #P224

Breast cancer-specific survival in 6,768 patients with lymph node-positive hormone receptor-positive invasive breast cancer and 21-gene Recurrence Score results in the SEER registries.
Shak S, Roberts M, Petkov VI, Miller DP, Howlader N, Cronin K, Penberthy L.
Poster #P225

Chemotherapy decision in node-positive ER+, early breast cancer after the new ASCO Guideline – Evidence for the 21-gene Recurrence Score assay.
Mamounas EP, Goldstein LJ, Penault-Llorca F, Roché H, Gluz O, Harbeck N, Nitz U, O’Shaughnessy J, Albain KS.
Poster #P226

A summary of head-to-head comparisons of patient risk classifications by the 21-gene Recurrence Score assay and other genomic assays for early breast cancer.
Varga Z, McCullough D, Lau A, Stöppler M, Baehner FL, Seidman AD.
Poster #P227

A pooled analysis of observational studies evaluating the impact of multi‐gene assay testing on adjuvant treatment decisions in ‘real‐world’ clinical practice for women with early breast cancer.
Millen S, Walshe J.
Poster #P233

Comparative budget impact assessment of the different breast cancer genomic tests in Germany.
Lux M, Schrauder M, Hildebrandt T, Nabieva N, Kümmel S, Blohmer JU.
Poster #P241

Clinical outcomes following Recurrence Score-based therapy in N+ ER+ breast cancer: A cohort study.
Stemmer S, Steiner M, Rizel S, Geffen D, Nisenbaum B, Peretz T, Isaacs K, Rosengarten O, Fried G, Svedman C, Ben-Baruch N.
Poster #P251

2017 ASCO GU - Orlando, FL

Prospective study of a 17-GENE RT-PCR-based assay for prediction of high risk pathology at radical prostatectomy.
Shore ND, Richardson T, Rosenberg S, Goldfischer E, Lu R, Shindel AW, Bennett J, Karsh LI, Korman H, Febbo PG, Denes BS

Validation of a 17-Gene Genomic Prostate Score (GPS) as a predictor of biochemical recurrence (BCR) in men with prostate cancer treated with radical prostatectomy (RP) in a community setting.
Van Den Eeden SK, Zhang N, Quesenberry CP, Han JS, Leimpeter AD, Shan J, Tsiatis AC, Lawrence JH, Febbo PG, Presti JC

Treatment patterns after the use of the 17-gene Genomic Prostate Score assay in Veterans newly diagnosed with clinically low-risk prostate cancer.
Lynch JA, Rothney M, Salup R, Ercole CE, Mathur S, Duchene D, Basler JW, Hernandez J, Liss MA, Porter MP, Wright JL, Risk MC, Efimova O, Denes BS, Febbo PG, Dash A

Influence of common comorbid conditions on a 17-gene assay for prediction of adverse pathology in clinically low-risk prostate cancer.
Cullen J, Sesterhenn I, Lawrence JH, Kuo HC, Srivastava S, Rosner IL, Zhang N, Brand TC, Shindel AW

2016 SABCS - San Antonio, TX

Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multi-center trial.
Bear HD, Wan W, Robidoux A, Rubin P, Limentani S, White, Jr. RL, Granfortuna J, Hopkins JO, Oldham D, Rodriguez A, Sing AP. #P2-10-04

Discovery of molecular predictors of late breast cancer specific events in ER+, node+ breast cancer – new transcriptome expression whole gene analysis of the phase III adjuvant trial SWOG S8814.
Albain KS, Crager MR, Barlow WE, Baehner FL, Bergamaschi A, Rae JM, Ravdin PM, Tripathy D, Gralow JR, Livingston RB, Osborne CK, Ingle JN, Pritchard KI, Davidson NE, Carey LA, Cherbavaz DB, Sing AP, Shak S, Hortobagyi GN, Hayes DF. #PD7-07.

21-gene Recurrence Score in patients with primary metastatic ER+ HER2- breast cancer.
Barinoff J, Anastasiadou L, Brandi C, Junker-Stein A, Silbermann J, Langenfeld M, Fortmann C, Thill M. #Poster OT3-04-04.

SEER study of breast cancer-specific mortality in patients with poorly differentiated tumors treated based on recurrence score results.
Petkov VI, Miller DP, Howlader N, Baehner FL, Penberthy L, Shak S. #PD7-06.

The 21-gene assay in the decision impact assessment of ER+, HER2- Breast cancer: A French real life prospective study.
Gligorov J, Dohollou N, Mouysset JL, Laplaige P, Fignon A, Lafuma A, Michaud P. #P6-07-28.

Real-world clinical experience and outcomes in patients with early-stage breast cancer treated according to the 21-gene Recurrence Score result.
Sing AP, Rothney M, Svedman C, Shak S, Baehner FL. #P6-09-08.

The impact of the 21 gene recurrence score (RS) on chemotherapy prescribing in estrogen receptor (ER) positive, lymph node positive early stage breast cancer in Ireland.
Keegan NM, Milewski M, Kelly CM, Murphy V, Chao C, Walsh J, Kennedy MJ, O'Connor M, Murphy C, O'Reilly S, Keane M, Duffy K, Hennessy B, Morris PG. #OT3-04-03.

2016 ESMO - Copenhagen, Denmark

First prospective multicenter Italian study on the impact of the 21-gene Recurrence Score® (RS) in adjuvant clinical decisions for ER + /HER2- early breast cancer patients.
M. Dieci, V. Guarner, M. Mion, G. Tortora, P. Morandi, S. Gori, L. Merlini, C. Oliani, F. Pasini, G. Bonciarelli, E. Orvieto, P. Del Bianco, G. De Salvo, P. Conte

Use of Oncotype DX Recurrence Score (RS) reduces chemotherapy (CT) beyond treatment decisions using Ki67-based determinations of luminal A and B breast cancer subtypes: a retrospective study in the Spanish population.
L. Garcia-Estevez, E. Hernandez, D. Acosta, F. Lopez-Rios, M. Prieto Pozuelo, I. Calvo

Breast cancer-specific survival in >4,600 patients with lymph node-positive (LN+) hormone receptor-positive (HR+) invasive breast cancer (BC) and 21-gene recurrence score (RS) results in the SEER registries.
D. P. Miller, M. Roberts, I. Petkov , S. Shak, N. Howlader, K. Cronin, L. Penberthy

The impact of the 21-gene assay in the Czech Republic on adjuvant chemotherapy (CT) recommendations and costs in estrogen receptor positive (ER+) early stage breast cancer (ESBC) patients with grade 2 tumors and risk factors.
K. Petrakova, L. Petruzelka, M. Holanek, T. Svoboda, M. Palacova, Z. Bielcikova, Z. Zbozinkova

Outcome disparities by age and 21-gene recurrence score (RS) result in hormone receptor positive (HR+) breast cancer (BC).
S. Shak, D. P. Miller, N. Howlader, N. Gliner, W. Howe, N. Schussler, K. Cronin, F. L. Baehner, L. Penberthy, V. I. Petkov

First prospectively-designed outcome study in estrogen receptor (ER)+ breast cancer (BC) patients (pts) with N1mi or 1-3 positive nodes in whom treatment decisions in clinical practice incorporated the 21-gene recurrence score (RS) result.
S. M. Stemmer, M. Steiner, S. Rizel, D. Geffen, B. Nisenbaum, T. Peretz, L. Soussan-Gutman, A. Bareket-Samish, K. Isaacs, O. Rosengarten, G. Fried, C. Svedman, S. Shak, N. Liebermann, N. Ben-Baruch

Analytical performance of a new liquid biopsy mutation panel for detection of clinically actionable variants.
C. Svedman, G. Alexander, A. Bergamaschi, J. Han, P. B. Harrington, C. Ku, Y. Ma, W. Gibb, A. Dei Rossi, L. Shen, A. D. Goddard, D. A. Eberhard, K. M. Clark-Langone

Budget impact analysis of the 21-gene assay (Oncotype DX® breast cancer) for the breast cancer treatment in the Basque country.
M. G. Toribio, J. Mar, E. Galve, I. Alvarez, A. Lahuerta, G. Unanue, O. Ibarrondo, P. Novas, N. Ancizar, L. Larburu , M. Hidalgo, J. Arango, C. Churruca, A. Plazaola, I. Perez, P. Purificación Martínez del Prado, S. Dominguez, A. Paisan

Prospective evaluation of the impact of the 21-gene recurrence score® assay on adjuvant treatment decisions for women with node-positive breast cancer in Ontario, Canada.
S. Torres, M. Trudeau, S. Gandhi ,E. Warner, S. Verma, K. Pritchard, T. Petrella, E. Slodkowska, M. Hew-Shue, C. Chao, A. Eisen

2016 ASCO - Chicago, IL

Association of PSA and number of cores positive with likelihood of adverse pathology at radical prostatectomy based on a 17-gene expression assay. 
Bonham M, Nightingale B, Tharayanil A, Denes BS, Rothney M, McCullough D, Bennett J, Febbo PG, Tsiatis AC; Abstract #e16570

Dissemination of 21-gene assay testing among female breast cancer patients in the US. 
Cronin K, Petkov VI, Howlader N, Howe W, Schussler NC, Kurian AW, Penberthy L; Abstract #6553

Effect of Oncotype DX Recurrence Score (RS) on chemotherapy (CT) decision-making by providing information beyond intrinsic subtypes in both luminal A and B breast cancer (BC) patients (pts): A retrospective study in the Spanish population. 
Garcia-Estevez L, Hernandez E, Acosta D, Lopez-Rios F, Prieto M, Calvo I; Abstract #e12013

Prognostic impact of 21 Gene Recurrence Score, IHC4, and central grade in high-risk HR+/HER2- early breast cancer (EBC): 5-year results of the prospective Phase III WSG PlanB trial.
Gluz O, Nitz U, Christgen M, Kates RE, Clemens M, Kraemer S, Nuding B, Reimer T, Aktas B, Kümmel S, Just M, Stefek A, Lorenz-Salehi F, Krabisch P, Liedtke C, Svedman C, Shak S, Wuerstlein R, Kreipe HH, Harbeck N, West German Study Group; Abstract #556

Clinical use of the 21-gene assay and patient experiences in early-stage breast cancer.
Katz SJ, Friese CR, Li Y, Deapen D, Hamilton AS, Ward KC, Kurian AW, iCanCare Study Investigators; Abstract #6501

Tailored neoadjuvant epirubicin and cyclophosphamide (EC) and nanoparticle albumin-bound paclitaxel (nab-P) in breast cancer. 
Khasraw M, Mukaro VR, West L, White K, Rippy E, Brandt C, Tobler R, Murphy CC, Collins IM, Baron-Hay SE, Ashley DM, Patil S; Abstract #e12515

A 17-gene genomic prostate score (GPS) as a predictor of biochemical (BCR) and clinical recurrence (CR) in men with surgically treated intermediate- and high-risk prostate cancer (PCa). 
Klein EA, Brand T, Rosner IL, Zhang N, Crager M, Maddala T, Febbo PG, Thomas S, Gormley M, Ricci DS, Falzarano SM, Magi-Galluzzi C, Cullen J, Sesterhenn I, Lawrence HJ; Abstract #5049

Improving risk stratification among veterans with newly diagnosed, clinically low-risk prostate cancer using the 17-gene genomic prostate score assay. 
Lynch JA, Rothney M, Salup R, Ercole CE, Mathur S, Duchene D, Basler JW, Hernandez J, Liss MA, MP, Wright JL, Risk MC, Garzotto M, Efimova O, Kemeter MJ, Denes BS, Febbo PG, Dash A; Abstract #e16611

Compliance with guidelines and factors associated with ordering the 21-gene breast cancer assay. 
Petkov VI, Howlader N, Cronin K, Kurian AW, Penberthy L; Abstract #6552

Outcome disparities by age and 21-gene recurrence score (RS) in hormone receptor positive (HR+) breast cancer (BC). 
Petkov VI, Miller DP, Howlader N, Gliner N, Howe W, Schussler NC, Cronin K, Baehner FL, Penberthy L, Shak S; Abstract #574

The impact of the 21-gene assay in the Czech Republic on adjuvant chemotherapy (CT) recommendations and costs in estrogen receptor positive (ER+) early stage breast cancer (ESBC) patients with grade 2 tumors and risk factors. 
Petrakova K, Petruzelka LB, Holanek M, Svoboda T, Palacova M, Kolarova I, Bielcikova Z, Zbozinkova Z; Abstract #e12061

Breast cancer specific survival in patients with node-positive hormone receptor positive invasive breast cancer and Oncotype DX recurrence score results in the SEER database. 
Roberts M, Petkov VI, Miller DP, Shak S, Howlader N, Cronin K, Penberthy L; Abstract #6575

Impact of the 21-gene Recurrence Score assay on the adjuvant treatment of breast cancer patients with 1-3 positive lymph nodes in an academic centre in Ontario. 
Torres S, Trudeau ME, Gandhi S, Warner E, Verma S, Pritchard KI, Petrella TM, Hew-Shue M, Chao C, Eisen A; Abstract #e12026

2016 EBCC – Amsterdam, Netherlands

Prospective WSG Phase III PlanB trial: Clinical outcome at 5 year follow-up and impact of 21 Gene Recurrence Score result, central/local-pathological review of grade, ER, PR and Ki-67 in HR+/HER2- high risk node-negative and -positive breast cancer patients.
Gluz O, Nitz U, Christgen M, Kates R, Clemens M, Kraemer S, Nuding B, Aktas B, Kümmel S, Reimer T, Lorenz-Salehi F, Krabisch P, Just M, Augustin D, Liedtke C, Svedman C, Shak S, Wüerstlein R, Kreipe H, Harbeck N

2016 EAU – Munich, Germany

Morphological and Molecular Pathway-Based Analysis of Gleason Score 7 Prostate Cancer Using a 17-Gene Expression Assay.
Bonham M, McCullough D, Lu R, Bennett J, Febbo P, Tsiatis AC

2016 AUA – San Diego, CA

The Biomarkers of Biochemical and Clinical Recurrence in Prostate Cancer Following Radical Prostatectomy - Performance of a 17-gene Genomic Prostate Score Assay and Tests for PTEN Loss.
Magi-Galluzzi C, Bonham M, Tsiatis AC, Falzarano S, Dee A, Maddala T, Knezevic D, Febbo PG, Lawrence HJ, Klein E

2016 ISPOR – Washington D.C.

Impact of the 17-gene Genomic Prostate Score assay on standardizing treatment of newly diagnosed, clinically low risk prostate cancer patients within the Veterans Health Administration.
Lynch J, Rothney M, Salup R, Ercole CE, Mathur SC, Duchene D, Basler JW, Gutierrez A, Hernandez J. Liss MA, Porter MP, Wright JL, Risk MC, Garzotto M, Efimova O, Barrett L, Kemeter M, Denes B, Febbo P, Dash A

2016 ASCO GU - San Francisco, CA

Patient-Specific Meta-Analysis (MA) of Two Validation Studies to Predict Pathologic Outcomes in Prostate Cancer (PCa) Using a 17-Gene Genomic Prostate Score (GPS)
Cooperberg M, Brand TC, Simko J, Sesterhenn I, Zhang N, Crager M, Maddala T, Lawrence JH, Febbo PG, Srivastava S, Chan JM, Cullen J, Carroll P

A 17-Gene Genomic Prostate Score (GPS) as a Predictor of Biochemical (BCR) and Clinical Recurrence (CR) in Men with Surgically Treated Intermediate- and High-Risk Prostate Cancer (PCa)
Klein EA, Zhang N, Crager M, Maddala T, Febbo PG, Thomas S, Gormley M, Ricci DS, Falzarano SM, Magi-Galluzzi C, Lawrence JH

2015 SABCS - San Antonio, TX

Association of TILs with Clinical Parameters, Recurrence Score, and Prognosis in Patients with Early HER2-Negative Breast Cancer (BC) – A Translational Analysis of the Prospective WSG PlanB Trial
Liedtke C, Gluz O, Heinisch F, et al
2015; Abstract P2-07-01

Prospective Trial of Endocrine Therapy Alone in Patients with Estrogen Receptor Positive, HER2-Negative, Node-Negative Breast Cancer: Results of the TAILORx Low Risk Registry
Sparano JA, Gray RJ, Makower DF, et al
2015; Abstract P2-08-01

Successful Whole Transcriptome Analysis of 25-Year-Old Breast Tumor Samples from the Phase III Trial SWOG8814 by Next Generation Sequencing (NGS): Standardized Analytical Methods for Exploratory and Validation Studies
Cherbavaz DB, Hayes DF, Qu K, et al
2015; Abstract P5-07-01

Real-Life Analysis Evaluating 1594 N0/Nmic Breast Cancer Patients for Whom Treatment Decisions Incorporated the 21-Gene Recurrence Score Result: 5-Year KM Estimate for Breast Cancer Specific Survival with Recurrence Score Results ≤30 is >98%
Stemmer SM, Steiner M, Rizel S, et al
2015; Abstract P5-08-02

Breast Cancer Specific Survival in 38,568 Patients with Node Negative Hormone Receptor Positive Invasive Breast Cancer and Oncotype DX Recurrence Score Results in the SEER Database
Shak S, Petkov VI, Miller DP, et al
2015; Abstract P5-15-01

Fulvestrant Plus Anastrozole as Neoadjuvant Therapy in Postmenopausal Women with Hormone Receptor Positive Early Breast Cancer
Khan QJ, Barr JA, Britt AS, et al
2015; Abstract P5-13-03

The 12-Gene DCIS Score Assay: Impact on Radiation Treatment (XRT) Recommendations and Clinical Utility
Manders JB, Kuerer HM, Smith BD, et al
2015; Abstract P5-17-03

Molecular Predictors of Outcome on Adjuvant CAF Plus Tamoxifen (T) vs T in Postmenopausal Patients (pts) with ER+, Node+ Breast Cancer – Transcriptome Expression Analysis of the Phase III Trial SWOG8814
Albain KS, Crager MR, Barlow WE, et al
2015; Abstract S3-02

2015 ESMO GI - Barcelona, Spain

Validation Study of the 12-Gene Recurrence Score (RS) in Patients (pts) with Stage II and III Colon Cancer (CC) Without Adjuvant Chemotherapy; SUNRISE Study
Ikeda M, Yamanaka T, Yamazaki K, Yamaguchi K, Muro K, Kusumoto T, Uetake H, Sato T, Kato T, Nishina T, Kanazawa A, Oki E, Chao C, Maddala T, Krishnakumar J, Akagi K, Ochiai A, Ohashi Y, A. Ohtsu A, Yoshino T
2015; Abstract.

2015 AACR - Salt Lake City, UT

Analysis of Tumor DNA in Urine as a Highly Sensitive Liquid Biopsy for Patients with Non-Muscle Invasive Bladder Cancer (NMIBC)
Resnick MJ, Lopatin M, Shore N, Lam PN , Helfand B, Abramson RD, Crager M, Bonham M, Tezcan H, Clark-Langone K, Silk C, Michelson S, Alexander G, Febbo P
2015; Abstract.

2015 ASCO - Chicago, IL

Evaluation of the Contribution of Individual Gene Groups to a 17-Gene Prognostic Prostate Cancer Signature
Knezevic D, Lu R, Burke E, Rothney M, Zhang N, Lawrence HJ, Febbo PG
2015; Abstract.

Oncotype DX Recurrence Score Distribution Among Breast Cancer Patients Harboring a Germline Mutation in the BRCA1/2 Genes
Lewin R, Rizel S, Hendler D, Neiman V, Ben-Aharon I, Liebermann N, Margel D, Zoref D, Sulkes A, Yerushalmi R
2015; Abstract.

Results of the Turkish Prospective Multi-Center Study Utilizing the 21-Gene Oncotype DX Assay: Decision Impact Analysis
Ozmen V, Atasoy A, Gokmen E, Ozdogan M, Guler EN, Uras C, Ok E, Demircan O, Isikdogan A, Pilanci KN, Ordu C, Duman O, Ates O, Sen F, Kara H, Oz B, Saip P
2015; Abstract.

Risk After Local Excision Alone for DCIS Patients
Rakovitch E, Nofech-Mozes S, Hanna W, Baehner FL, Saskin R, Butler SM, Tuck A, Sengupta S, Elavathil L, Jani PA, Bonin M, Chang M, Robertson S, Slodkowska E, Fong CH, Anderson JM, Jamshidian F, Cherbavaz DB, Shak S, Paszat LF
2015; Abstract.

Correlation Between the DCIS Score and Traditional Clinicopathologic Features in the Prospectively-Designed Ontario Population-Based Validation Study
Rakovitch E, Nofech-Mozes S, Hanna W, et al
2015; Abstract.

Effect of the 21-Gene RT-PCR Assay on Treatment Administered in Early-Stage, Node-Positive (N+) Breast Cancer
Reichert J, Patton J, Chao CY
2015; Abstract.

Recurrence Score and Clinicopathologic Characteristics of TAILORx Participants by Race and Ethnicity
Zlobinsky Rubinstein MM, Gray EJ, Sparano JA, Zujewski J, Whelan TJ, Albain KS, Hayes DF, Geyer CE Jr., Dees EC, Perez ES, Keane MM, Vallejos C, Goggins TF, Mayer IA, Brufsky A, Toppmeye D, Kaklamani VG, Atkins JN, Berenberg JL, Sledge GW
2015; Abstract.

Hormone Receptor Discordance Between Local and Central Pathology with RT-PCR Analysis: Results from Multicenter Phase III WSG-PlanB Trial
Von Schumann R, Gluz O, Nitz U, Clemens M, Luebbe K, Aktas B, Just M, Noesselt T, Henschen S, Hackmann J, Lorenz-Salehi F, Freese K, Svedman C, Kates RE, Kreipe HH, Harbeck N, Liedtke C
2015; Abstract.

2015 AUA - New Orleans, LA

Comparison of Different Analytical Platforms for the Identification of Tumor DNA in the Urine of Bladder Cancer Patients
Resnick MJ, Abramson RD, Yoshizawa C, Lam PN, Shore N, Tezcan H
2015; Abstract.

The 17gene Genomic Prostate Score (GPS) Assay: Initial Clinical Experience of 4,000 Patients
Katz A, Ho A, Burke E, Denes B, Lu R, Rothney M, Bonham M, Tsiatis A, Lawrence J, Febbo P
2015; Abstract.

A Multi-Center Comparison of a 17-Gene Genomic Prostate Score (GPS) as a Predictor of Outcomes in African-American (AA) and Caucasian (CA) Men with Clinically Localized Prostate Cancer (PCa)
Cullen J, Sesterhenn I, Klein E, Mohler J, Carroll P, Cooperberg M, Zhang N, Maddala T, Knezevic D, Tsiatis A, Lawrence HJ, Febbo P
2015; Abstract.

Clinical Benefits and Costs of a 17-gene Assay Designed to Assess Risk of Adverse Pathology after Positive Prostate Biopsy
Dall'Era M, Michalopoulos SN, Denes BS, Tighe J, Hornberger J
2015; Abstract.

Association Between a 17-Gene Genomic Prostate Score and Multi-Parametric Prostate MRI in Men with Low and Intermediate Risk Prostate Cancer (PCa)
Leapman M, Westphalen A, Ameli N, Lawrence J, Febbo P, Cooperberg M, Carroll P
2015; Abstract.

2015 EAU - Madrid, Spain

The 17-Gene Genomic Prostate Score Assay: Initial Commercial Experience of 4,000 Patients
Burke EM, Denes BS, Lu R, Rothney M, Tsiatis AC, Lawrence HJ, Febbo PG
2015; Abstract.

2015 USCAP - Boston, MA

The Relationship Between Quantitative HER2 Gene Expression by the 21-Gene RT-PCR Assay and Adjuvant Trastuzumab (H) Benefit in NCCTG (Alliance) N9831
Perez EA, Butler SM, Dueck AC, Baehner FL, Jamshidian F, Cherbavaz DB, Thompson EA, Shak S, Kaufman PA, Davidson NE, Gralow J, Asmann Y, Ballman K
2015; Abstract.

Prediction of Local Recurrence in Ductal Carcinoma in Situ: Clinical Validation of DCIS Score
Nofech-Mozes S, Rakovitch E, Baehner FL, Saskin R, Butler SM, Tuck AB, SenGupta SK, Elavathil L, Jani P, Bonin M, Chang MC, Slodkowska E, Shak S, Paszat LF, Hanna W
2015; Abstract.

A Laboratory Comparison of the 21-Gene Assay and PAM50-ROR
Bailey H, Alvarado M, Baehner FL, Prasad C, Rothney M, Chervabaz D, Sing AP, Svedman C
2015; Abstract.

Central Lab HER2 Testing By RT-PCR, IHC, & FISH For Quality Assurance (QA) In Locally HER2-Negative (HER2-), ER-Positive Invasive Breast Carcinoma (IBC) With Adjacent In Situ Carcinoma (IS)
Tan V, Lu R, Tharayanil A, Nightingale B, Sing AP, Anderson JM, Tsiatis AC, Bailey H, Bonham MJ, Pingitore A, Yaziji H, Joseph P, Shak S, Baehner FL
2015; Abstract.

A 16-Gene Signature for Assessing Risk of Recurrence in Renal Cancer: Performance Beyond Conventional Pathologic Factors and Impact of Tumor Heterogeneity on Assay Results
Bonham MJ, Koscielny S, Lopatin M, Svedman C, Verkarre V, Radulescu C, Neuzillet Y, Hemmerle I, Olivier TM, Martini JF, Williams JA, Tsiatis AC, Knezevic D, Lebret T, Goddard A, Mejean A, Escudier B
2015; Abstract.

The 12-Gene Colon Cancer Assay: Experience with 12,776 Stage II Patients
Bailey H, Tharayanil A, Lu R, et al.
2015; Abstract 576.

2015 St. Gallen International Breast Cancer Conference - Vienna, Austria

The 21-Gene Breast Cancer Assay: A Roadmap of Clinical Evidence
Bayt T, Burke E, Rothney M, Sing AP
2015; Abstract P248.

Predicting Risk After Breast-Conserving Surgery Alone For DCIS Patients
Rakovitch E, Nofech-Mozes S, Hanna W, Baehner FL, Saskin R, Paszat L
2015; Abstract P252.

Predicting Late Distant Recurrence Risk in ER+ Breast Cancer after Five Years of Tamoxifen
Mamounas E, Wolmark N, Baehner FL, Butler SM, Tang G, Jamshidian F, Sing AP, Shak S, Paik S
2015; Abstract P264.

Quantitative Gene Expression by RT-PCR in Classic and Variant Lobular Carcinoma in ER+ Breast Cancer
Anderson JM, Yoshizawa C, Tan V, Bailey H, Tsiatis A, Bonham M, Sing AP, Shak S, Baehner F
2015; Abstract P034.

Quantitative RT-PCR Gene Expression in the Special Subtypes of Invasive Breast Cancer
Tan V, Baehner F, Yoshizawa C, Anderson J, Bailey H, Tsiatis A, Sing AP, Shak S
2015; Abstract P035.

Central Lab HER2 Testing by RT-PCR, IHC & FISH in Locally HER2-Neg, ER+ IBC with In Situ Carcinoma
Tan V, Lu R, Tharayanil A, Anderson J, Tsiatis A, Bailey H, Bonham M, Pingitore A, Shak S, Baehner F
2015; Abstract P032.

The MAGIC Survey: HR+, HER2– Breast Cancer (BC) Patients for Whom Multigene Assays May Be Valuable
Aapro M, De Laurentiis M, Linderholm B, Mamounas E, Markopoulos C , Martin M, Neven P, Rea D, Rouzier R, Thomssen C
2015; Abstract P105.

Risk Assessment by St.Gallen 2013 Recommendation and Oncotype DX: Results from the WSG PlanB Trial
Nitz U, Gluz O, Kreipe H, Christgen M, Kates RE, Clemens M, Kraemer S, Aktas B, Kuemmel S, Harbeck N
2015; Abstract P246.

Luminal Subtypes vs. Early Proliferation Response and Oncotype DX in Early Breast Cancer: Observations from the WSG-ADAPT HR+/HER2- Subprotocol
Gluz O, Nitz U, Christgen M, Kreipe H, Kates RE, Kuemmel S, Braun M, Schumacher C, Wuerstlein R, Harbeck N
2015; Abstract P231.

A Laboratory Comparison of the 21-gene Assay and PAM50-ROR
Alvarado, M, Prasad C, Rothney M, Cherbavaz D, Sing AP, Baehner F, Svedman C, Markopoulos C
2015; Abstract P247.

Economic Impact of 21-Gene Recurrence Score Testing on Early Stage Breast Cancer in Ireland
Smyth L, Watson G, Kelly CM, Keane M, Kennedy MJ, O'Reilly S, O'Connor M, Verleger K, O'Reilly S, Walshe JM
2015; Abstract P253.

Usefulness of the 21-Gene Assay to Guide Adjuvant Chemotherapy Decision-Making: Geneva Experience
Bodmer A, Hugli A, Diebold Berger S, Favet L, Guetty Alberto M, Exquis B
2015; Abstract P241.

2015 Miami Breast Cancer Conference

The 21-Gene Breast Cancer Assay in Small (<1cm) Tumors
Russell CA, Rothney R, Sing AP
2015; Abstract.

The 12-Gene DCIS Score Assay and Quantitative ER, PR, and HER2 Across Histologic Subtypes: Experience in the First 2.5 Years
Sing AP, Tan V, Bailey H, Anderson JM, Rothney M, Baehner FL
2015; Abstract.

Association of Estrogen Receptor (ER) Levels and Prediction of Antiproliferative Effect of Hormone Therapy (HT) in Lower ER-Expressing Tumors
Sing AP, Dixon JM, Turnbull A, Renshaw L, Loman CA, Arthur L, Thomas JS, Young O , Murray J, Cameron S
2015; Abstract.

Clinical Utility of the 12-Gene Ductal Carcinoma in Situ (DCIS) Score Assay: Impact on Treatment (tx) Recommendations
Alvarado M, Carter D, Guenther JM, Hagans J, Leonard C, Manders J, Sing AP, Chang E, Cherepanov D, Schultz M
2015; Abstract.

2015 ASCO GU - Orlando, FL

The Association of a 17-Gene Genomic Prostate Score (GPS) with Adverse Pathology and Biochemical Recurrence in Localized Prostate Cancer (PCa): Comparison of African-American (AA) and Caucasian (CA) Patients.
Cullen J, Rosner IL, Brand TC, Ali A, Chen Y, Zhang N, Tsiatis AC, Knezevic D, Maddala T, Lawrence HJ, Febbo PG, Srivastava S, Sesterhenn I, Mcleod DG
2015; Abstract.

Association Between a 17-gene Genomic Prostate Score and Multi-Parametric Prostate MRI in Men with Low and Intermediate Risk Prostate Cancer (PCa)
Leapman MS, Westphalen AC, Ameli N, Lawrence HJ, Febbo PG, Cooperberg MR, Carroll P
2015; Abstract.

Evaluation of the Contribution of Individual Gene Groups to a 17-Gene Prognostic Prostate Cancer Signature
Knezevic D, Lu R, Burke E, Rothney M, Zhang N, Febbo PG, Lawrence HJ
2015; Abstract.

Robustness of the 16-Gene Signature for Prediction of Recurrence-Free Interval (RFI) in Localized Clear Cell Renal Cell Carcinoma (ccRCC)
Escudier BJ, Koscielny S, Maddala T, Svedman C, Verkarre V, Radulescu C, Neuzillet Y, Timsit MC, Hemmerlé I, Tsiatis AC, Bonham M, Knezevic D, Martini J, Williams JA, Lebret T, Goddard AD, Mejean A
2015; Abstract.

2015 IPCU - Vail, CO

The 17-gene Genomic Prostate Score Assay: Initial Commercial Experience of 2,500 Patients.
Denes B, Burke E, Rothney M, Tsiatis AC, Bonham M, Lawrence HJ, Febbo PG
2015; Abstract.

The Development and Validation of a 17-Gene Genomic Prostate Score (GPS) as a Predictor of Outcome in Newly Diagnosed Prostate Cancer
Lawrence HJ, Burke E, Knezevic D, Maddala T, Tsiatis AC, Zhang N, Klein EA, Carroll PR, Cooperberg MR, Cullen J, Sesterhenn IA, Febbo PG
2015; Abstract.

2015 ASCO GI - San Francisco, CA

Recurrence Score Result Distributions in Stage II Colon Cancers of African American (AA) and Caucasian (CA) Patients
Govindarajan R, Posey J, Chao CY, Lu R, Jadhav T, Javed AY, Javed A, Mahmoud FA, Osarogiagbon RU, Manne U
2015; Abstract .

2014 Society of Urologic Oncology - Bethesda, MD

Next Generation Sequencing of DNA from Urine Detects Multiple Bladder Tumor−Derived Alterations and Additional Changes That Suggest Tumor Heterogeneity
Richard D. Abramson, Gregory E. Alexander, Ellen M. Beasley, Francois Collin, Michael Crager, Andrew Dei Rossi, Joseph Dorado, Adam Friedman, Bill Gibb, Jennie Jeong, Col Jones, Chin−Jen Ku, Yan Ma, John Morlan, Kunbin Qu, Aibing Rao, Aaron Scott, Haluk Tezcan, Neal Shore, Phillip G. Febbo
2014; Abstract .

2014 SABCS - San Antonio, TX

Association of estrogen receptor (ER) levels and prediction of antiproliferative effect of hormone therapy (HT) in lower ER-expressing tumors.
Dixon JM, Turnbull A, Renshaw L, Rothney MP, Loman CA, Arthur L, Thomas JS, Young O, Murray J, Williams L, Sing AP, Cameron D
2014; Abstract P3-06-35.

Global quantitative measures using next-generation sequencing for breast cancer presence outperform individual tumor markets in plasma.
Beasley EM, Abramson RD, Alexander GE, Chan D, Bradley K, Collin F, Crager M, Dei Rossi A, Dorado J, Friedman A, Gibb WJ, Jeong J, Jones C, Ku CJ, Ma Y, Morlan J, Qu K, Rao A, Scott A, Tezcan H
2014; Abstract P4-02-08.

Prognostic impact of discordance between different risk assessment tools in early breast cancer (recurrence score, central grade, Ki67): Early outcome analysis from the prospective phase III WSG-PlanB trial.
Nitz U, Gluz O, Kates RE, Hofmann D, Kreipe HH, Christgen M, Shak S, Clemens M, Kraemer S, Aktas B, Kuemmel S, Reimer T, Kusche M, Heyl V, Lorenz-Salehi F, Just M, Liedtke C, Wuerstlein R, Harbeck N
2014; Abstract P4-11-01.

The Multidisciplinary Application of Genomics in Clinical Practice (MAGIC) survey: Identification of early-stage hormone receptor-positive, HER2-breast cancer patients for whom multigene assays may be valuable.
Aapro M, Bargallo Rocha JE, De Laurentiis M, Elizalde R, Landherr L, Linderholm B, Mamounas T, Markopoulos C, Martin M, Neven P, Petrovsky A, Rea D, Rouzier R, Smit V, Svedman C, Thomssen C
2014; Abstract P6-08-06.

ADAPT - Adjuvant Dynamic marker-Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer.
Nitz U, Gluz O, von Schumann R, Hofmann D, Kates RE, Kuemmel S, Braun M, Schumacher C, Nuding B, Aktas B, Forstbauer H, Maass N, Rezai M, Kraemer S, Warm M, Wuerstlein R, Harbeck N
2014; Abstract OT3-2-04.

2013 ASCO - Chicago, IL

Evidence for a field effect in early prostate cancer (PCa): gene expression profiles in normal appearing prostate tissue (NT) adjacent to tumor (T) are predictive of clinical outcome.
Klein E, Maddala T, Lawrence J, Magi-Galluzzi C
2013; Abstract #5029

Real-world comparative economics of a 12-gene assay for prognosis in stage II colon cancer
Yu T, Alberts S.R., Behrens R. J., et al.
2013; Abstract #3640

Impact of the Recurrence Score (RS) result and mismatch repair status (MMR) on agreement between oncologists (MDs) for stage II colon cancer (CC) recurrence risk (RR) assessment: A novel clinical utility endpoint for prognostic markers
Kelley R.K, Lopatin M, Hwang J, et al.
2013; Abstract #e14569

Association of the colon cancer recurrence score with treatments received in patients with stage II colon cancer: The Clalit Health Services experience
Brenner B, Geva R, Beny A, et al.
2013; Abstract #e22111

Fusion transcript discovery in formalin-fixed paraffin-embedded human breast cancer tissues and its relation to tumor progression
Ma Y, Ambannavar R, Stephans J, et al.
2013; Abstract #11018

The relationship between quantitative HER2 gene expression by the 21-gene RT-PCR assay and adjuvant trastuzumab (H) benefit in NCCTG (Alliance) N9831
Perez E. A., Butler S. M., Dueck A. C, et al.
2013; Abstract #520

Ethnic differences in tumor proliferation in women with early-stage breast cancer
Kalinsky K, Lim E.A., Andreopoulou E, et al.
2013; Abstract #560

Phase II trial evaluating the use of 21-gene recurrence score (RS) to select preoperative therapy in hormone receptor (HR)-positive breast cancer
Zelnak A. B., Murali S, Styblo T. M., et al.
2013; Abstract #562

Initial results from the 21-gene breast cancer assay registry: A prospective observational study in patients (pts) with ER+, early-stage invasive breast cancer (EBC)
Vacirca J.L, Tsai M. L., Brufsky A, et al.
2013; Abstract #565

A comparative analysis of distant recurrence risk assessments by Oncotype DX recurrence score alone and integrated with clinicopathologic factors in early-stage breast cancer
Kelly C.M., Beamish R, McCaffrey J, et al.
2013; Abstract #598

A retrospective study in the Spanish population with Oncotype dx recurrence score (RS) in breast cancer patients with positive and negative-lymph nodes
Estevez LG, Calvo I, Abad MF, et al.
2013; Abstract #e11531

ADAPT: Adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer
Harbeck N, Hofmann D, Gluz O, et al.
2013; Abstract #TPS655

2013 St. Gallen Breast Cancer Conference - St. Gallen, Switzerland

Review of traditional prognostic and predictive markers in early-stage breast cancer
Plun-Favreau J, Luthman S, C. Svedman C, et al.
2013; Abstract #P126

Pooled analysis of 4 European studies assessing the impact of Oncotype DX on treatment decisions
Albanell J, Gligorov J, Holt S.D, et al.
2013; Abstract #P138

Differences in Recurrence Score (RS) results between luminal A and luminal B breast cancer subtypes
Efrat N., Rizel S, Yerushalmi R, et al.
2013; Abstract #P141

A comparison of risk classification as assessed by the MammaPrint and Oncotype DX assays
Svedman C, Clough K, Poulet B, et al.
2013; Abstract #P145

The 21-gene breast cancer assay: summary of clinical evidence
Sing A.P., Baehner F.L., Yoshizawa C, et al.
2013; Abstract #P146

The Oncotype DX DCIS Score and quantitative gene expression for ER, PR, and HER2: 1,071 patients
Tan V, Bailey H, Tsiatis A, et al.
2013; Abstract #P147

The development of the DCIS Score: scaling and normalization in the Marin general population
Baehner F.L., Butler S.M., Yoshizawa C, et al.
2013; Abstract #P148

Oncotype DX VS clinicopathologic factors in breast cancer: the experience from Greece and Cyprus
Nasioulas G, Kesisis G, Razi E, et al.
2013; Abstract #P154

Impact of the Oncotype DX assay on decision-making in estrogen receptor positive early breast cancer
Jaafar H, Taher A, Quasmeh K, et al.
2013; Abstract #P156

Quantitative gene expression by RT-PCR in special histologic subtypes of invasive breast cancer
Bailey V, Tsiatas A, Yoshizawa C, et al.
2013; Abstract #P19

Quantitative gene expression by RT-PCR in classic and variant lobular carcinoma in ER+ breast cancer
Anderson J, Yoshizawa C, Watson D, et al.
2013; Abstract #P20

Retrospective analysis of treatment decisions in patients with intermediate Recurrence Score results
Fried G
2013; Abstract #P200

Budget impact analysis of the Oncotype DX Breast Cancer Test in France
Rouzier R, Laas E, Chéreau E, et al.
2013; Abstract #P208

Recurrence Score fo prognosis and prediction of paclitaxel benefit in node(+)/ER(+) breast cancer
Mamounas E.P, Tang G., Paik S, et al.
2013; Abstract #P213

Retropspective budget impact analysis on the use of Oncotype DX test in Ireland
Falahee M, Plun-Favreau J, Ercoli K.
2013; Abstract #P281

Cost-effectiveness analysis of the 21-gene breast cancer test in Mexico
J. Bargallo Rocha F. Lara Medina, R. Shaw Dulin, V. Pérez Sánchez
2013; Abstract #P283

Cost-effectiveness of Oncotype DX test vs current clinical practice: a Dutch cost perspective
Steuten R, Schutten M, Kip M, et al.
2013; Abstract #P284

Economic impact of the Oncotype DX results guided adjuvant treatments in Turkey
Rózsa K, Horváth Z, Juhos É, et al.
2013; Abstract #P286

Using the Recurrence Score in clinical practice: a HMO experience with a unified testing policy
Silverman N, Zick A, Beit-Or A, et al.
2013; Abstract #P287

Family life during and after breast cancer treatment: A European patient survey
Mimoun D, Elia E, Braybrooke J, et al.
2013; Abstract #P290

2012 ASCO - GI - San Francisco, CA

Effect of Oncotype DX Colon Cancer Test Results on Treatment Recommendations in Patients with Stage II Colon Cancer: Preliminary Results
Cartwright T, Chao C, Lopatin M, Bentley T, Broder M, Chang E
2012; Abstract #398

2012 ASCO - GU - San Francisco, CA

Identification of Prostate Cancer-Expressed MicroRNAs Associated with Clinical Recurrence and Prostate Cancer Specific Survival Following Radical Prostatectomy
Klein E, Kiefer M, Crager M, Magi-Galluzzi C, Falzarano S, Pelham R, Cherbavaz D, Baker J, Shak S, Lee M
2012; Abstract # 21

2012 ASCO - Chicago, IL

Evaluation of variables that may impact the use of Oncotype DX testing.
Szabo S, Gilmore J, Haislip S, Hassell R, Cooper J, Richardson S, Fitzgerald M, Feinberg B; Georgia Cancer Specialists PC, Atlanta, GA; Cardinal Health, Specialty Solutions, Dublin, OH; Genomic Health, Redwood City, CA
2012; Abstract #e11002

Can Oncotype DX recurrence score (RS) be used in luminal A and luminal B breast cancer patients (pts) to predict the likely benefit of chemotherapy? A retrospective study in the Spanish population.
García-Estevez L, Contreras A, Calvo I, Abad M, Cruz J, Perea S, Suárez A, López-Ríos F, Hidalgo M; Centro Integral Oncológico Clara Campal, Madrid, Spain; Centro Médico Guerra Méndez, Valencia, Venezuela; Dpto. Medicina Preventiva y Salúd Pública, UAM, Madrid, Spain
2012; Abstract #e11006

Evaluation of the Oncotype Dx recurrence score (RS) in hormone-positive ipsilateral breast tumor recurrences.
Wapnir I, Florero M; Stanford University, Stanford, CA
2012; Abstract #e11032

Correlation between the DCIS score and traditional clinicopathologic features in the prospectively designed E5194 clinical validation study.
Badve S, Gray R, Baehner F, Solin L, Butler S, Yoshizawa C, Shak S, Hughes L, Page D, Sledge G, Davidson N, Perez E, Ingle J, Wood W, Sparano J; Indiana University School of Medicine, Indianapolis, IN; Dana-Farber Cancer Institute, Boston, MA; Genomic Health, Redwood City, CA; Albert Einstein Medical Center, Philadelphia, PA; The Hope Center, Cartersville, GA; Vanderbilt University, Nashville, TN; Indiana University Simon Cancer Center, Indianapolis, IN; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN; Department of Surgery, Emory University, Atlanta, GA; Albert Einstein College of Medicine, Bronx, NY
2012; Abstract #1005

10-year update of E2197: Phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high-risk LN- breast cancer and the comparison of the prognostic utility of the 21-gene recurrence score (RS) with clinicopathologic features.
Sparano J, O'Neill A, Gray R, Perez E, Shulman L, Martino S, Badve S, Baehner F, Childs B, Yoshizawa C, Rowley S, Davidson N, Shak S, Goldstein L; Albert Einstein College of Medicine, Bronx, NY; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Jacksonville, FL; The Angeles Clinic and Research Institute, Santa Monica, CA; Indiana University School of Medicine, Indianapolis, IN; University of California, San Francisco, San Francisco, CA; Sanofi, Bridgewater, NJ; Genomic Health, Redwood City, CA; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Fox Chase Cancer Center, Philadelphia, PA
2012; Abstract #1021

Cost-effectiveness of the 21-gene recurrence score assay in the setting of multifactorial decision making for chemotherapy in early-stage breast cancer.
Reed S, Dinan M, Schulman K, Lyman G; Duke Clinical Research Institute, Durham, NC; Duke University, Durham, NC
2012; Abstract #1525

Validation of the 12-gene colon cancer recurrence score (RS) in NSABP C07 as a predictor of recurrence in stage II and III colon cancer patients treated with 5FU/LV (FU) and 5FU/LV+oxaliplatin (FU+Ox)
O'Connell M, Lee M, Lopatin M, Yothers G, Clark-Langone L, Millward C, Paik S, Sharif S, Shak S, Wolmark N; National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA; Genomic Health, Redwood City, CA; NSABP Biostatistical Center and University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA; National Surgical Adjuvant Breast and Bowel Project and Allegheny General Hospital, Pittsburgh, PA; National Surgical Adjuvant Breast and Bowel Project and Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh, PA
2012; Abstract #3512

Effect of the 12-gene colon cancer assay results on treatment recommendations in patients with stage II colon cancer
Cartwright T, Chao C, Lopatin M, Bentley T, Broder M, Chang E; Ocala Oncology, Ocala, FL; Genomic Health, Redwood City, CA; Partnership for Health Analytic Research, LLC, Beverly Hills, CA
2012; Abstract #3626

A prospective clinical utility study of the impact of the 21-gene recurrence score assay (Oncotype DX) in estrogen receptor positive (ER+) node negative (pN0) breast cancer in academic Canadian centers.
Davidson J, Cromwell I, Ellard S, Lohrisch C, Gelmon K, Shenkier T, Villa D, Lim H, Sun S, Taylor S, Taylor M, Czerkawski B, Hayes M, Ionescu D, Pope J, Berube J, Yoshizawa C, Chao C, Peacock S, Chia S; British Columbia Cancer Agency (Fraser Valley Centre), Surrey, BC, Canada; Canadian Centre for Applied Research in Cancer Control, Vancouver, BC, Canada; British Columbia Cancer Agency (Centre for the Southern Interior), Kelowna, BC, Canada; British Columbia Cancer Agency (Vancouver Centre), Vancouver, BC, Canada; Department of Pathology, British Columbia Cancer Agency (Vancouver Centre), Vancouver, BC, Canada; Genomic Health, Redwood City, CA; British Columbia Cancer Research Center, Vancouver, BC, Canada
2012; Abstract #549

Prospective comparison of recurrence score and independent central pathology assessment of prognostic tools in early breast cancer (BC): Focus on HER2, ER, PR, Ki-67 results from the phase III WSG-Plan B trial.
Gluz O, Kreipe H, Christgen M, Degenhardt T, Kates R, Liedtke C, Shak S, Clemens M, Salem M, Markmann S, Liedtke B, Aktas B, Henschen S, Pollmanns A, Krabisch P, Uleer C, Augustin D, Thomssen C, Nitz U, Harbeck N; West German Study Group; West German Study Group, Moenchengladbach, Germany; Hannover Medical School, Hannover, Germany; University Hospital Munich, Cologne, Germany; REK Consulting, Otterfing, Germany; University of Muenster, Muenster, Germany; Genomic Health, Redwood City, CA; Klinikum Mutterhaus, Trier, Germany; University Clinics of Cologne, Cologne, Germany; University Clinic of Rostock, Rostock, Germany; Evangelical Hospital, Bergisch Gladbach, Germany; Department of Gynecology and Obstetrics, University of Duisburg-Essen, Essen, Germany; Johanniter Clinics Stendal, Stendal, Germany; EKO, Oberhausen, Germany; Department of Gynecology and Obstetrics, Klinikum Chemnitz, Chemnitz, Germany; Gynecology Practice, Hildesheim, Germany; Klinikum Deggendorf, Deggendorf, Germany; Martin Luther University Halle, Halle, Germany; West German Study Group and Evangelical Hospital Bethesda, Moenchengladbach, Germany; West German Study Group and University of Munich, Munich, Germany
2012; Abstract #552

Obesity at diagnosis and breast cancer (BC) recurrence risk based on the 21-gene assay recurrence score (RS).
Ridolfi K, Zhang C, Onitilo A, Ledesma W, Andreason M, Engel K, Kim K, Wisinski K, Tevaarwerk A, Charlson J; Medical College of Wisconsin, Milwaukee, WI; University of Wisconsin Carbone Cancer Center, Madison, WI; Marshfield Clinic, Weston, WI
2012; Abstract #555

Impact of exogenous female hormone use (EHU) on breast cancer (BC) recurrence as assessed by the 21-gene assay (Oncotype DX).
Ledesma W, Onitilo A, Zhang C, Kim K, Andreason M, Charlson J, Ridolfi K, Engel J, Wisinski K, Millholland R, Dean J, Tevaarwerk A; University of Wisconsin Carbone Cancer Center, Madison, WI; Marshfield Clinic, Weston, WI; Medical College of Wisconsin, Milwaukee, WI; University of Wisconsin Hospital and Clinics Cancer Registries, Madison, WI; University of Wisconsin, Madison, WI
2012; Abstract #563

Prospective study of the impact of using the 21-gene recurrence score assay on clinical decision making in women with estrogen receptor-positive, HER2-negative, early-stage breast cancer in France.
Gligorov J, Pivot X, Naman H, Jacot W, Spaeth D, Misset JL, Largillier R, Sautiere JL, Roquancourt A, Pomel C, Rouanet P, Rouzier R, Penault-Llorca F; Francilian Breast Intergroup; APHP Tenon APREC, CancerEst, University Paris VI, Paris, France; University Hospital of Besancon, Besancon, France; Centre Azureen Cancerologie, Mougins, France; Centre Valdorel, Montpellier, France; Centre D'Oncologie De Gentilly, Gentilly, France; Hospital Saint Louis, Paris, France; Centre Azuréen de Cancérologie, Mougins, France; CHU Besançon, Besançon, France; APHP Hôpital Saint-Louis, Paris, France; Centre Jean Perrin, Clermont-Ferrand, France; Centre Val d'Aurellle, Montpellier, France; Tenon, Paris, France
2012; Abstract #568

Evaluation of Oncotype DX testing and subsequent patterns of care in patients (pts) with early-stage breast cancer (ESBC).
Fitzgerald M, Hassell R, Haislip S, Gilmore J, Richardson S, Cooper J, Szabo S, Feinberg B; Cardinal Health, Specialty Solutions, Dublin, OH; Georgia Cancer Specialists PC, Atlanta, GA; Genomic Health, Redwood City, CA
2012; Abstract #569

Evaluation of variables that may impact chemotherapy (CT) administration after determination of Oncotype DX (ODX) recurrence score (RS).
Bowen K, Gilmore J, Szabo S, Haislip S, Hassell R, Cooper J, Richardson S, Fitzgerald M, Feinberg B; Georgia Cancer Specialists PC, Atlanta, GA; Cardinal Health, Specialty Solutions, Dublin, OH; Genomic Health, Redwood City, CA
2012; Abstract #571

Rural versus urban differences among patients (pts) with hormone-receptor positive (HR+) breast cancer (BC) and a 21-gene assay recurrence score (RS).
Andreason M, Zhang C, Onitilo A, Charlson J, Ledesma A, Ridolfi K, Kim K, Wisinski K, Champeny T, Engel J, Millholland R, Dean J, Tevaarwerk A; University of Wisconsin, Madison, WI; Biostatistics, University of Wisconsin, Madison, WI; Marshfield Clinic, Weston, WI; Medical College of Wisconsin, Milwaukee, WI; University of Wisconsin Carbone Cancer Center, Madison, WI; University of Wisconsin Hospital and Clinics Cancer Registries, Madison, WI
2012; Abstract #6063

Relationship between Oncotype DX testing and the use of chemotherapy in high-risk patients (pts).
Wong W, Cooper J, Richardson S, Feinberg B; CareFirst BlueCross BlueShield, Baltimore, MD; Cardinal Health, Specialty Solutions, Dublin, OH; Genomic Health, Redwood City, CA
2012; Abstract #6098

2012 Advances in Genome Biology and Technology Conference - Marco Island, FL

Prognostic Biomarker Discovery using RNA-Seq in Two Cohorts of Breast Cancer Patients
D. Sinicropi, M.-L. Liu, J. Stephans, M. Pho, J.Jeong, A. Scott, R. Ambannavar, J. Morlan, R. Pelham, K. Qu, F. Collin, J. Baker
2012; Abstract #327

2012 ESMO - Vienna, Austria

Meta-analysis of prospective European studies assessing the impact of using the 21-gene recurrence score assay on clinical decision making in women with ER-positive, HER2-negative early stage breast cancer
J. Albanell, S. Holt, J. Gligorov, W. Eiermann, C. Svedman
2012; Abstract #252

Study of the impact of the 21-gene breast cancer assay on the use of adjuvant chemotherapy in women with breast cancer in a Mexican public hospital
J.E.R. Bargallo, F. Lara, R.J. Shaw Dulin, V. Perez-Sánchez, C. Villarreal-Garza, H. Maldonado-Martinez, A. Mohar-Betancourt, C. Yoshizawa, E. Burke, C. Chao
2012; Abstract #289

2011 AACR Annual Meeting - Orlando, FL

Transcriptome Profiling from Formalin-Fixed, Paraffin-Embedded Tumor Specimens by RNA-Seq
Kunbin Qu*, John Morlan, Jim Stephans, Xitong Li, Joffre Baker, Dominick Sinicropi
2010; From Beyond the Genome: The true gene count, human evolution and disease genomics:Boston, MA, USA. 11-13 October 2010.

2011 SABCS - San Antonio, TX

Abstract #OD06-02
Cost-Effectiveness Evaluation of the Oncotype DX Breast Cancer Assay in Clinical Practice in the UK
Holt SDH, Bennett H, Bertelli G, Valentine WJ, Phillips CJ. Prince Philip Hospital, Llanelli, United Kingdom; Cardiff Research Consortium, Cardiff, United Kingdom; Singleton Hospital, Swansea, United Kingdom; Ossian Health Economics and Communications, Basel, Switzerland; Swansea University, Swansea, United Kingdom.
2011;

Abstract #P1-07-11
Consistency and Control in Clinical Assay Technology over Time: The Oncotype DX Recurrence Score and Assessment of Single Gene Expression Levels
Baehner FL, Butler SM, Anderson JM, Ballard J, Tan V, Shak S. Genomic Health, Inc., Redwood City, CA; UCSF, San Francisco, CA.
2011;

Abstract #P1-07-22
A Venezuelan Study of Breast Cancer Estrogen Receptor, Progesterone Receptor and HER2 Receptor Expression by the Standard Method, Immunohistochemistry (IHC), Compared to a New Method, Quantitative Reverse Transcription Polymerase Chain Reaction (RT-PCR)
Marin C-EM, Ramirez AC, Baehner FL, Yoshizawa C, Acosta MM. Fundacion BADAN, Caracas, Miranda, Venezuela; Genomic Health, Redwood City, CA.
2011;

Abstract #P1-10-04
Cost-Utility of the 21-Gene Breast Cancer Assay (Oncotype DX) in the Irish Healthcare Setting
Lacey L, Chien R, Hornberger J. Lacey Solutions Ltd, South Strand, Skerries, County Dublin, Ireland; Cedar Associates LLC, Menlo Park, CA; Columbia University, New York, NY; Stanford University, Stanford, CA.
2011;

Abstract #P1-10-05
Is the 21-Gene Breast Cancer Test (Oncotype DX) Cost-Effective?
Pronzato P, Plun-Favreau J. Istituto Naz.le Ricerca Cancro, Genova, Italy; Genomic Health International Sàrl, Geneva, Switzerland.
2011;

Abstract #P1-10-06
Economic Analysis of Chemotherapy Costs for Adjuvant Therapy in Breast Cancer in France
Chereau E, Vataire A-L, Laas E, Genin A-S, Aballéa S, Rouzier R. Tenon - APHP, Paris, France; Creativ-Ceutical, Paris, France.
2011;

Abstract #P2-12-26
Impact of the Recurrence Score on Adjuvant Decision-Making in ER-Positive Early Breast Cancer - Results of a Large Prospective Multicentre Decision Impact Study in Node Negative and Node Positive Disease
Rezai M, Eiermann W, Kümmel S, Kühn T, Warm M, Friedrichs K, Schneeweiss A, Markmann S, Eggemann H, Hilfrich J, Jackisch C, Witzel I, Eidtmann H, Kaufmann M, Blohmer JU. Luisenkrankenhaus, Düsseldorf, Germany; Rotkreuzklinikum, München, Germany; Kliniken Essen-Mitte, Essen, Germany; Klinikum Esslingen, Esslingen, Germany; Krankenhaus Holweide, Köln, Germany; Brustzentrum, Hamburg, Germany; Universitätsklinikum, Heidelberg, Germany; Universitätsklinikum, Rostock, Germany; Universitätsklinikum, Magdeburg, Germany; Eilenriedeklinik, Hannover, Germany; Klinikum Offenbach, Offenbach, Germany; Universitätsklinikum Eppendorf, Hamburg, Germany; Universitätsklinikum, Kiel, Germany; Univesitätsklinikum, Frankfurt, Germany; Sankt Gertrauden-Krankenhaus, Berlin, Germany.
2011;

Abstract #P2-12-26
Comparison of Oncotype DX Recurrence Scores between Surgical and Core Biopsy Specimens in Breast Cancer Patients
Stull TS, Goodwin MC, Anderson JM, Baehner FL, Sing AP, Yoshizawa CN, Barrio AV, Frazier TG. The Bryn Mawr Hospital, Bryn Mawr, PA; Genomic Health, Inc, Redwood City, CA.
2011;

Abstract #P4-09-18
Australian Decision Impact Study: The Impact of Oncotype DX Recurrence Score (RS) on Adjuvant Treatment Decisions in Hormone Receptor Positive (HR+), Node Negative (N0) and Node Positive (N+) Early Stage Breast Cancer (ESBC) in the Multidisciplinary Clinic (MDC)
de Boer RH, Baker C, Speakman D, Mann B. Royal Melbourne Hospital, Melbourne, Victoria, Australia; Austin Hospital, Melbourne, Victoria, Australia; Peter MacCallum Cancer Institue, Melbourne, Victoria, Australia; Royal Melbourne and Royal Women's Hospital, Melbourne, Victoria, Australia.
2011;

Abstract #P5-13-09
Correlation of Oncotype DX Recurrence Scores with Pathologic Response Following Neoadjuvant Ixabepilone and Cyclophosphamide in Patients with HER2-Negative Breast Cancer: A Sarah Cannon Research Institute Phase II Trial
Yardley DA, Peacock NW, Hendricks C, Huh SY, Ketchum S, Chao C, Yoshizawa C, Burris III HA, Hainsworth JD. Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; Center for Cancer and Blood Disorders, Bethesda, MD; Providence Medical Group, Terre Haute, IN; Mercy Hospital, Portland, ME; Genomic Health, Redwood City, CA.
2011;

Abstract #P5-14-03
Genomic Comparison of Paired Primary Breast Carcinomas and Macrometastatic Lymph Node Metastases Using Quantitative RT-PCR by Oncotype DX: Assessment of the Recurrence Score and Quantitative Single Genes
Boolbol SK, Kirstein L, Harshan M, Klein P, Cohen J-M, Chadha M, Baehner FL, Malamud SC. Beth Israel Medical Center, New York, NY; Genomic Health Inc., Redwood City, CA
2011;

Abstract #P5-14-26
Results from a Prospective Clinical Study on the Impact of Oncotype DX on Adjuvant Treatment Decision Making in a Cohort of 142 UK Patients
Holt S, Bertelli G, Brinkworth E, Durrani S, Jones S, Khawaja S, Laggner U, Moe M, Pudney D, Pitcher S, Rolles M, Sharaiha Y, Whelan S. Prince Philip Hospital, Llanelli, Carmarthenshire, United Kingdom; Singleton Hospital, Swansea, West Glamorgan, United Kingdom; Bronglais Hospital, Aberystwyth, Ceredigion, United Kingdom
2011;

Abstract #P5-18-03
First Interim Toxicity Analysis of the Randomized Phase III WSG Plan B Trial Comparing 4xEC-4xDoc Versus 6xTC in Breast Cancer Patients with HER2 Negative Breast Cancer (BC)
Nitz U, Gluz O, Krepe H, Liedtke B, Aktas B, Henschen S, Pollmanns A, Krabisch P, Zuna I, Shak S, Thomsseen C, Harbeck N. West German Study Group, Moenchengladbach, Germany; Breast Centre Niederrhein/Bethesda Hospital, Moenchengladbach, Germany; Bethesda Hospital, Wuppertal, Germany; Medizinishce Hochschule, Hannover, Germany; Evangelical Hospital, Bergisch Gladbach, Germany; University Hospital, Essen, Germany; Johanniter Hospital, Stendal, Germany; Evangelical Hospital, Oberhausen, Germany; City Hospital Chemnitz, Chemnitz, Germany; Genomic Health Inc, Redwood City, Germany; University Hospital Halle/Saale, Halle/Saale, Germany; University Hospital Cologne, Cologne, Germany.
2011;

Abstract #PD03-09
Breast Cancer Recurrence Risk Probed by Whole Transcriptome Next Generation Sequencing in 136 Patients
Baker J, Liu M-L, Crager M, Stephans J, Pho M, Jeong J, Scott A, Ambannavar R, Morlan J, Pelham R, Qu K, Mena RR, Esteban J, Collin F, Sinicropi D. Genomic Health Inc., Redwood City, CA; Providence St. Joseph Medical Center, Burbank, CA.
2011;

Abstract #S4-06
A quantitative multigene RT-PCR assay for predicting recurrence risk after surgical excision alone without irradiation for ductal carcinoma in situ (DCIS): A prospective validation study of the DCIS score from ECOG E5194
Solin LJ, Gray R, Baehner FL, Butler S, Badve S, Yoshizawa C, Shak S, Hughes L, Sledge G, Davidson N, Perez EA, Ingle J, Sparano JA, Wood W. Albert Einstein Medical Center, Philadelphia, PA; Eastern Cooperative Oncology Group, Boston, MA; Genomic Health, Inc., Redwood City, CA; Indiana University, Indianapolis, IN; The Hope Center, Cartersville, GA; University of Pittsburgh, Pittsburgh, PA; Mayo Clinic Jacksonville, Jacksonville, FL; Mayo Clinic Rochester, Rochester, MN; Albert Einstein College of Medicine, Bronx, NY; Emory University, Atlanta, GA.
2011;

Abstract #S4-3
Prospective comparison of risk assessment tools in early breast cancer (recurrence score, uPA/PAI-1, central grade, and luminal subtypes): Final correlation analysis from the phase III WSG-Plan B trial
Gluz O, Kreipe H, Degenhardt T, Kates R, Christgen M, Liedtke C, Shak S, Clemens M, Markmann S, Uleer C, Augustin D, Thomssen C, Nitz U, Harbeck N. West German Study Group, Moenchengladbach, Germany; Medizinische Hochschule, Hannover, Germany; University of Muenster, Muenster, Germany; Genomic Health Inc, Redwood City; Klinikum Mutterhaus, Trier, Germany; Klinikum Suedstadt, Rostock, Germany; Gynecology Practice, Hildesheim, Germany; Klinikum Deggendorf, Deggendorf, Germany; University of Halle/Saale, Halle/Saale, Germany; Bethesda Clinics, Moenchengladbach, Germany; University of Cologne, Cologne, Germany.
2011;

2010 SABCS - San Antonio, TX

Abstract #S4-9
Comparing the prediction of chemotherapy benefit in patients with node-negative, ER-positive breast cancer using the recurrence score and a new measure that integrates clinical and pathologic factors with the recurrence score
Tang G, Costantino JP, Crager M, Shak S, Wolmark N. NSABP, Pittsburgh, PA, Genomic Health Inc., Redwood City, CA.
2010;

Abstract #P2-09-06
Meta-Analysis of the Decision Impact of the 21-Gene Breast Cancer Recurrence Score in Clinical Practice
Hornberger J, Chien R. Stanford University, CA; Cedar Associates LLC, Menlo Park, CA.
2010;

Abstract #P3-10-01
Quantitative Gene Expression Analysis in a Large Cohort of Estrogen-Receptor Positive Breast Cancers: Characterization of the Tumor Profiles in Younger Patients (<= 40 yrs) and in Older Patients (>= 70 yrs)
Shak S, Baehner FL, Stein M, Chen I, Yoshizawa C, Watson D, Swain SM. Genomic Health, Inc, Redwood City, CA; Young Survival Coalition, New York, NY; Washington Hospital Center, Washington DC.
2010;

Abstract #P3-10-12
Pilot Phase of the Randomized PlanB Trial: Prospective Comparison of Molecular Classification, Oncotype DX® and Clinical-Pathological Characteristics in Hormone-Receptor (HR) Positive Primary Breast Cancer
Gluz O, Kreipe H, Christgen M, Salem M, Clemens M, Markmann S, Liedtke B, Barinoff J, Aktas B, Henschen S, Lübbe K, Shak S, Baehner R, Liedtke C, Nitz U, Harbeck N, on Behalf of the WSG/AGO Plan B Investigators. West German Study Group/Bethesda Wuppertal, Moenchengladbach, Germany; University of Hannover, Germany; University of Cologne, Dept. OB&GYN, Breast Centre, Germany; Klinikum Mutterhaus der Borromaeerinnen, Trier, Germany; University Hospital Rostock, Germany; Ev. Hospital, Bergisch Gladbach, Germany; Dr. Horst-Schmidt Hospital, Wiesbaden, Germany; University Hospital Essen, Germany; Johanniter Hospital, Stendal, Germany; University Hospital Muenster, Germany; Hospital Henriettenstiftung, Dept. OB&GYN, Hannover, Germany; Breast Center Niederrhein, Bethesda Hospital, Moenchengladbach, Germany; Genomic Health, Inc., Redwood City.
2010;

Abstract #P3-10-13
Prognostic Value of Genomic Analysis after Neoadjuvant Chemotherapy for Breast Cancer
Mayer EL, Shak S, Miller K, Rugo H, Carey L, Ryabin N, Pomeroy C, Yoshizawa C, Winer EP, Burstein HJ. Dana-Farber Cancer Institute, Boston, MA; Genomic Health, Inc, Redwood City, CA; Indiana University Simon Cancer Center, Indianapolis; University of California San Francisco, Helen Diller Family Comprehensive Cancer Center; University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill.
2010;

Abstract #P3-10-15
Quantitative Gene Expression by RT-PCR in Classic and Variant Forms of Lobular Carcinoma in Estrogen Receptor Positive Invasive Breast Cancer
Anderson JM, Yoshizawa C, Winer EP, Watson D, Millward C, Tan V, Shak S, Baehner FL. Genomic Health, Redwood City, CA; Dana-Farber Cancer Institute, Boston, MA; University of California, San Francisco.
2010;

2010 ASCO - Chicago, IL

Abstract #509
Recurrence risk of node-negative and ER-positive early-stage breast cancer patients by combining recurrence score, pathologic, and clinical information: A meta-analysis approach.
G. Tang, J. Cuzick, C. Wale, J. P. Costantino, M. Crager, S. Shak, N. Wolmark, M. Dowsett, J. F. Forbes; National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA; Queen Mary, University of London, London, United Kingdom; Genomic Health, Redwood City, CA; National Surgical Adjuvant Breast and Bowel Project and Allegheny General Hospital, Pittsburgh, PA; The Royal Marsden Hospital, London, United Kingdom; University of Newcastle, Newcastle-upon-Tyne, United Kingdom

Abstract #511
Potential biologic causes of the racial survival disparity in adjuvant trials of ER-positive breast cancer.
K. S. Albain, W. E. Barlow, S. Shak, G. N. Hortobagyi, D. F. Hayes, for The Breast Cancer Intergroup of North America; Loyola University Medical Center, Maywood, IL; Cancer Research and Biostatistics, Seattle, WA; Genomic Health, Redwood City, CA; University of Texas M. D. Anderson Cancer Center, Houston, TX; University of Michigan Medical Center, Ann Arbor, MI

Abstract #6075
The recurrence score and chemotherapy treatment in node-positive, ER+ early-stage breast cancer patients in Israel.
S. Klang, N. Liebermann, S. Rizel, N. Ben-Baruch, S. Merling, L. Soussan-Gutman, R. Bugarini, C. Chao, S. Shak; Clalit Health Services, Tel Aviv, Israel; Rabin Medical Center, Petah Tikva, Israel; Kaplan Medical Center, Rehovot, Israel; Teva Pharmaceutical Industries, Netanya, Israel; Genomic Health, Redwood City, CA

Abstract #e11077
Effect of 21-gene recurrence score results on treatment recommendations in patients age 65 and older with lymph node-positive, estrogen receptor-positive breast cancer.
R. Oratz, C. Chao, S. Skrzypczak, C. Ory, M. Broder; New York University School of Medicine, New York, NY; Genomic Health, Redwood City, CA; Partnership for Health Analytic Research, Beverly Hills, CA

Abstract #4501
Identification of prognostic genomic markers in patients with localized clear cell renal cell carcinoma (ccRCC).
B. I. Rini, M. Zhou, H. Aydin, P. Elson, T. Maddala, D. Knezevic, L. Parodi, R. M. Bukowski, W. F. Novotny, J. W. Cowens; Cleveland Clinic, Cleveland, OH; Genomic Health, Redwood City, CA; Pfizer, Inc., New York, NY; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

Abstract #3503
Comparison of molecular and pathologic features of stage II and stage III colon cancer in four large studies conducted for development of the 12-gene colon cancer recurrence score.
M. J. O'Connell, I. C. Lavery, R. G. Gray, P. Quirke, D. J. Kerr, M. Lopatin, G. A. Yothers, M. Lee, K. Clark-Langone, N. Wolmark; National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA; Cleveland Clinic Foundation, Cleveland, OH; University of Birmingham, Birmingham, United Kingdom; University of Leeds, Leeds, United Kingdom; Sidra Medical and Research Center, Doha, Qatar; Genomic Health, Redwood City, CA; National Surgical Adjuvant Breast and Bowel Project Biostatistical Center and University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA; National Surgical Adjuvant Breast and Bowel Project and Allegheny General Hospital, Pittsburgh, PA
2010;

Abstract #3097
Association of vorinostat with decrease in gene expression of proliferation-related genes in tumors from women with newly diagnosed breast cancer.
V. Stearns, L. K. Jacobs, T. N. Tsangaris, Z. Cheng, S. Slater, M. J. Fackler, C. Chao, R. Bugarini, E. Gabrielson, N.E. Davidson; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD; Johns Hopkins School of Medicine, Baltimore, MD; Anne Arundel Medical Center, Annapolis, MD; Genomic Health, Redwood City, CA; University of Pittsburgh Cancer Institute, and University of Pittsburgh Medical Center Cancer Center, Pittsburgh, PA

2008 ASCO Annual Meeting―Chicago, IL

Evaluation of Tumor Gene Expression and K-Ras Mutations in FFPE Tumor Tissue as Predictors of Response to Cetuximab in Metastatic Colorectal Cancer
JB Baker, D Dutta, D Watson, T Maddala, S Shak, EK Rowinsky, L Xu, E Clark, DJ Mauro, S Khambata-Ford

2008; Abstract #3512

2006 ASCO Annual Meeting - Atlanta, GA

Relationship Between Tumor Gene Expression and Recurrence in Stage II/III Colon Cancer: Quantitative RT-PCR Assay of 757 Genes in Fixed Paraffin-Embedded (FPE) Tissue
MJ O’Connell, S Paik, G Yothers, JP Costantino, JW Cowens, KM Clark, J Baker, J Hackett, D Watson, N Wolmark
2006; Abstract #3518 : Poster Discussion

2003 ASCO Annual Meeting―Chicago, IL

Quantitative Gene Expression in Non-Small Cell Lung Cancer from Paraffin-Embedded Tissue Specimens: Predicting Response to Gefitinib, an EGFR Kinase Inhibitor
RB Natale, S Shak, N Aronson, S Averbuch, W Fox, D Luthringer, K Clark, J Baker, M Cronin, DB Agus

2003; Abstract #763 : Oral Presentation

Oncotype DX My Colon Cancer Coach